Detailed Rationale

Crisil Ratings has revised its outlook on the long-term bank facilities of Emcure Pharmaceuticals Limited (Emcure) to ‘Positive’ from ‘Stable’, while reaffirming the rating at ‘Crisil AA-’. The rating on the short-term facility has been reaffirmed at ‘Crisil A1+’.

 

The revision in outlook factors expectations of a sustained improvement in the business risk profile of the company, supported by healthy double-digit growth in revenues as seen in the past two fiscals, led by diversified revenue streams across geographies, that cover formulations, biologics and APIs. The group holds a strong market position as one of the top 15 pharmaceutical companies in India with a market share of 2.18% (MAT March 2025). Furthermore, in line with Crisil Ratings expectations, the company’s financial risk profile has also seen a substantial improvement, through robust networth position and debt reduction post IPO. These strengths are partially offset by the group’s working capital requirements and exposure to intensifying competition in the domestic and regulated markets as well as regulatory and legal risks.

 

Operating income grew by 18% on-year to Rs 7,910 crore in fiscal 2025, from Rs 6,672 crore in previous fiscal led by organic growth of ~12% and strategic addition of Sanofi’s brand that contributed to the balance ~6%. The first three months of current fiscal also reported healthy growth in revenues to Rs 2,101 crore, showcasing a growth of 16% on-year. For the full year, Crisil Ratings expects the revenues to grow by ~10-13%, higher than the industry average of ~7-9% growth, supported by diversification into new therapies, healthy product mix and strong brand presence in the domestic market. During the current fiscal, the company has made conscious investments for foraying into therapies such as dermatology and consumer wellness in the domestic market which will support the growth going forward. The business risk profile derives further comfort from Emcure’s minimal exposure to the US market, safeguarding it from any tariff risks.

 

Operating profits have remained steady at 18-19% over the last couple of years. Margins have improved to 19.84% in the first three months of current fiscal, led by improving operating efficiencies. Over the medium term, an improvement in profit levels is expected, supported by improving mix of chronic to acute therapy and better operating efficiencies.

 

Emcure’s financial risk profile has improved substantially as the company repaid a substantial portion of its debt from the proceeds of its initial public offering (IPO) last fiscal also supported by a robust tangible networth profile of Rs 3,456 crore as on March 31, 2025. This also led to substantial improvement in the credit metrices, with net debt/earnings before interest, tax, depreciation and ammortisation (EBITDA) improving to 0.31 times in fiscal 2025 as against the high of 1.23 times in previous fiscal (1.37 times in FY2023). During the current fiscal, Emcure has acquired the remaining stake (~20.42%) in its subsidiary, Zuventus Healthcare Ltd (Zuventus, Crisil AA-/Positive/A1+) for a consideration of Rs 724.9 crore. With expectations of continued improvement in cash generation and prudent funding of capital expenditure, debt metrics are likely to remain at healthy levels over the medium term. Any sizeable debt-funded acquisition or elongation in working capital, which alters the debt protection metrics, will remain a key monitorable.

Analytical Approach

Crisil Ratings has combined the business and financial risk profiles of Emcure and its subsidiaries, collectively referred to as Emcure group, because these entities have common line of business, and inter-company transactions of sale/purchase.

 

Also, Crisil Ratings has amortised intangible assets and goodwill on acquisition of Mantra Pharma Inc. (Mantra) over five years; profit after tax (PAT) and net worth have been adjusted accordingly.

 

Please refer Annexure - List of Entities Consolidated, which captures the list of entities considered and their analytical treatment of consolidation.

Key Rating Drivers - Strengths 

Improving business risk profile, supported by geographic diversity in revenue: Emcure group has a diversified revenue profile, with 47% of revenue accruing from domestic market in fiscal 2025 and remaining from the international markets. The group has an established market position in the domestic formulations market with a market share of 2.18% as per AIOCD MAT (All India Organisation of Chemists & Druggists) as on March 31, 2025, and had six brands in the top 300 brands in the domestic market. It continues to maintain a leading position in Gynecology, Anti-infectives, Pain management/ Analgesics and Cardiology   The company’s export revenues too have grown at a steady double digit CAGR as it has increased its presence in Europe and Canada, over the years, by establishing front-end marketing networks through acquisitions of Tillomed Laboratories Limited (UK), Marcan Pharmaceuticals Inc (Canada) and Mantra Pharma Inc. (Canada). These factors have further aided the company registering a better growth rate as compared to the industry. Emcure's operating income increased by 18% to Rs 7,910 crore, driven by 12% organic growth and a ~6% contribution from Sanofi's brand additions. Revenues increased by 16% to Rs 2,101 crore in the first quarter this fiscal. The company has been focusing on diversification strategies by expanding into therapies such as dermatology and consumer wellness in the domestic market, which will aid the business risk profile going forward. Going forward, growth is expected to be in the mid-teens for the current fiscal year, driven by diversification, a healthy product mix, and strong brand presence, while minimal US exposure will shield it from tariff risks.

 

Experienced management team, accredited manufacturing facilities and established R&D capabilities: The promoter and chief executive officer, Mr Satish Mehta, is a first-generation entrepreneur with more than four decades of experience in the pharma sector. The second generation has been actively involved in the strategy and growth initiatives of the business for over a decade. Additionally, the group has a team of highly qualified professionals and scientists to support operations, strategy, and other functions, and drive future growth.

 

Emcure group has 13 manufacturing facilities across India, which produces a range of pharma/ biopharma products in varied dosage forms, including oral solids, oral liquids, injectables, including complex injectables such as liposomal and lyophilized injectables, biotherapeutics and complex APIs, including chiral molecules, iron molecules and cytotoxic products. The facilities are approved/accredited by various regulatory bodies including, USFDA, UK MHRA (United Kingdom), Health Canada, , ANVISA Brazil and are compliant with current Good Manufacturing Practices (“GMP”) certificates from regulators including Health Canada, the World Health Organization (“WHO”), the Agency for Medicinal Products and Medical Devices of Croatia (“HALMED Croatia”), the National Institute of Pharmacy and Nutrition of Hungary (“NIPN Hungary”) and the Therapeutic Goods Administration of Australia (“TGA Australia”).

 

Emcure group has five R&D facilities with 552 qualified scientists. The group’s R&D focus along with manufacturing skills, developed through long track record of contract manufacturing for international pharma companies, has helped establish its presence in regulated and emerging markets. Besides, its generic formulations research in complex injectables, established expertise in chiral chemistry and focus on biopharma business demonstrates its strong R&D capabilities.

 

Healthy financial risk profile: Financial risk profile has improved substantially post repayment of debt from the IPO proceeds and a robust networth size. The company prepaid ~ Rs.600 crores of debt from the IPO proceeds with outstanding debt of Rs 731 crore as on March 31, 2025. Adjusted networth stood at Rs 3,456 crore leading to a gearing of 0.21 times as on March 31, 2025 against the highs of over 1.18 times seen in the previous year. Further, the net debt/Ebitda metrices improved to 0.31 times in fiscal 2025 from the highs of 1.23 times in fiscal 2024 and 1.67 times in fiscal 2023. During fiscal 2025, Emcure added Sanofi’s portfolio in the cardio therapeutic segment. Gennova acquired licensing rights from HDT Biocorp for an overall total consideration of ~Rs.150 crore in FY2025. The annual capex plan for the current fiscal is of Rs 350-400 crore for operational, maintenance and capacity expansion. Additionally, during the current fiscal, the company also acquired its balance stake of 20.42% in the subsidiary co. Zuventus, for a value of Rs 725 crore. Continued healthy cash generation will aid in scheduled repayment of its outstanding debt. That said, any sizeable debt funded acquisitions, including brands, which can impact debt metrics will remain monitorable.

Key Rating Drivers - Weaknesses 

Exposure to intensifying competition and increasing legal and regulatory risks: Emcure group generates significant proportion of total sales through the regulated markets. The generics business in the regulated markets is highly competitive and has various legal and regulatory risks. Players in the regulated generics markets are vulnerable to pricing pressure on account of entry of several cost-competitive Indian players. Furthermore, growing competition, may limit improvement in profitability. Also, owing to the nature of products, Emcure group like many of its peers is vulnerable to litigations filed by regulators among others. In addition to this, any price-control measures of the government in the branded segment may weaken the domestic formulation growth and remains monitorable.

 

While the US business under Avet has been demerged, Emcure group remains exposed to any future litigation in the US and other markets. Any sizeable outflow towards settlement of the same remains monitorable. However, Emcure has entered into an Indemnification Deed with Avet, whereby from the Effective Date (as defined in the Scheme of Arrangement) Avet has agreed to indemnify, defend and hold harmless the company and its directors, officers, employees, agent, representatives and shareholders, as applicable, (“Indemnified Parties”) from and against any and all the losses suffered or incurred by the Indemnified Parties, which arises out of, results from or in connection with any claim and any loss suffered by the Indemnified Party on account of breach by Avet or its subsidiaries and affiliates of any covenants, undertakings and/or obligations of the Indemnification Deed, and in relation to losses arising out of certain identified claims.

 

Working capital intensive nature of operations: Operations are working capital intensive, as reflected in gross current assets of ~200 days as on March 31, 2025, driven by inventory and receivables of ~110 and ~94 days, respectively. The group operates in multiple geographies, has multiple plants and has a large product portfolio; hence, it needs to maintain sizeable inventory to ensure adequate supply.

Liquidity Strong

Emcure group continues to generate sufficient cash accruals of over Rs 1,000 crore annually which shall remain sufficient to cover annual debt repayment obligations in Emcure and its subsidiaries and fund the annual capex plans. Cash and equivalents were healthy at Rs 265 crore as on June 30, 2025. The sanctioned working capital limit at consolidated level, was utilised ~32% on average during the twelve months through June 2025.

Outlook Positive

Crisil Ratings believes Emcure’s business and financial risk profile will further improve with steady growth in revenue supported by a improving therapy mix and improved profitability aiding steady improvement in the credit metrices.

Rating sensitivity factors

Upward factors

• Sustained healthy revenue growth of around 14-15% supported through improvement in therapy and product mix, with steady improvement in profitability
• Improved working capital management aiding in further reduction in debt levels, and benefitting debt metrics

 

Downward factors

• Sustained underperformance in business and decline in operating profits to below ~18% levels
• Stretch in working capital cycle or large, debt-funded capex or acquisitions, or indirect support provided to group companies, significantly impacting debt metrics
• Sizeable outgo of funds to settle any litigations, impacting debt metrics or liquidity

About the Company

Emcure was incorporated by Mr. Satish Mehta in 1981; the company commenced operations in 1983 in Pune, Maharashtra. The group has 13 manufacturing facilities across India and 5 R&D centres. The manufacturing facilities can manufacture pharmaceutical and biopharmaceutical products across a wide range of dosage forms, including oral solids, oral liquids, injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs.

 

It has presence in domestic, regulated as well as emerging markets. It enjoys the alliance of multinational corporations and has established front-end presence in several countries through its subsidiaries. It has subsidiaries in UK, Canada, Dubai, Italy, Germany, South Africa etc. It markets formulations in key chronic therapeutic segments such as cardiology, gynecology, oncology, anti-HIV and neurologyanti-diabetes; also, it has presence in acute segments such as anti-infective, pain management, dermatology, gynecology and pediatrics. Key brands such as Orofer, Pause, Bevon, Maxtra, Metpure, Proxym and Asomex and Ferium are well-established in the domestic market. 

 

The company got listed on the Indian stock exchange on July 10, 2024 and the promoters hold ~77.50% stake in Emcure, while the rest is owned by public shareholders including Bain Capital owing 8.6%, as on June 2025. The company also successfully completed the offer for sale (OFS) and raised Rs 1,152 crore through stake sale of the promoter and promoter group, besides Bain Capital (which earlier held over 13% stake).

 

In the first quarter of fiscal 2026, the company reported revenue of Rs 2,101 crore (Rs 1,815 crore in the corresponding period of fiscal 2025) and a net profit of Rs 215 crore (Rs 153 crore in the corresponding period of fiscal 2025)

Key Financial Indicators (consolidated; Crisil Ratings adjusted numbers)

As on / for the period ended March 31		2025	2024
Operating income	Rs crore	7,910	6,672
PAT*	Rs crore	553	411
PAT margin	%	7	6.2
Adjusted debt / adjusted net worth*	Times	0.21	1.18
Adjusted Interest coverage	Times	9.03	5.4

*Adjusted for amortisation of intangible assets and goodwill on acquisition of Rs. 154 crore in fiscal 2025 and Rs. 116 crore in fiscal 2024

Any other information: Not applicable